The company had ~$57M as of their last quarterly call, plus ~$12M from the recent sale of shares, plus ~$22M from a loan for a total of approximately ~$90M in the bank. They have been burning cash at around ~$50M a year so even if they continue at this pace(and I don't see that happening since the most $$$ phase three trial is basically done) they have enough cash to last for at least 1.8 years which I think should be enough cash to get them through FDA approval of their drug.
This is a company that has ~$90M in cash and a ~$180M market cap with a drug that in my opinion has a ~95% chance of getting approved and will generate ~$400M in peak revenue for one indication. There are also potentially other revenue generating indications.
Is it just me or is this company extremely undervalued???
Stop Loss orders and fear go hand in hand. Got to love it when you're a buyer. :)
BobDole Sold! "BobDole 3 hours ago: BTW, disclosure that I sold VSTM after the 8K filing of "ATM dilution". FYI."
Isn't this the same moron that was toouting how unbeleivabley cheap the shares were, yada yada yada? What a moron!!!
Don't sell. Just pure market panic by the big boys. Nothing has changed. See you at $8!
I believe the stock has been declining because a secondary offering is coming. Any thoughts about this?
Who thinks this will hit $8 before it hits $4?
Thinking that about 1/3 of daily volume is Cantor 'at the market' sales of new shares.
this week has sucked
BobDole says: "BobDole2 hours ago: Crey, Yahoo, you clowns. Want to guess which stock I'm up big today?"
All you fools who believed BobDole should do as he did...SELL VSTM and BUY HMNY!!!!
Seems like VSTM has ongoing $75M ATM. In today's 8-K form you can find that "Since June 30, 2017, the Company has sold 2,562,449 shares of the Company’s common stock pursuant to this program and has received proceeds of approximately $12.8 million, net of commissions paid." It means that average price they sold was $5/share. They could have sold it only after positive phase 3 data announcement or since September 6. Therefore it explains why share price is not moving above $5+ and it means no need for stock offering since they have an ATM.
Here's BobDole's strategy...buys a stock that popped the day before, then posts it on multiple message boards to drive it up so he can sell it...click his name and you will see...VSTM, AMD, NVDA, etc...it's a good plan indeed!
Just a little background - VSTM's early focus was killing cancer stem cells (defactinib). An early ccompetitor was Stemcentrix (Rova-T) and was bought last year by guess who - "AbbVie" -- AbbVie bought Stemcentrix last year for $10 billion dollars who had no successful trials and no revenue -- AbbVie is not afraid to pull the trigger.
Remember AbbVie's and Infinity Pharmaceuticlas - had a tie up to develop "duvelisib" for CLL (Sept. 2014). It didn't work out. To recap - Infinity was to receive an upfront payment of $275 million, with up to $530 million in additional payments for certain milestones, including up to $405 million for the achievement of milestones through the first commercial sale of duvelisib.
Think about that!
So, in Nov. 2016 VSTM comes in buys up the rights to Duvelisib from Infinity for a mere $28mil in milestones and single digit royalties. Just recently Sept. 2017, VSTM completes a very successful phase 3 trial for duvelsib and refractory/relapsed CLL. Wonder how AbbVie feels today about letting duvelisib get away for absolutely nothing?
Think AbbVie might circle back around? I wouldn't bank on it, but I'm sure they are fully aware of the highly favorable DUO results with Duvelsib/CLL. The pulled the trigger when they should have exercised a little more patience.
pre market for real? wow!?
Secured $25 Million Loan Facility – In March 2017, Verastem entered into a Loan and Security Agreement with Hercules Capital, Inc. for up to $25.0 million in financing. Verastem received the first $2.5 million of financing under the Loan and Security Agreement when the transaction closed. The proceeds will be used for Verastem’s ongoing research and development programs and for general corporate purposes. Additional tranches of up to $22.5 million in aggregate will be available subject to certain conditions, including positive data from the Phase 3 DUO clinical trial evaluating duvelisib in patients with relapsed or refractory CLL. Info "report first quarter 2017 financial results"
Like this post if you agree that BobDole is a scammer.
You can comment too please :)
In my opinion this is one of the most undervalued small cap biotech stocks out there. ~$200m market cap is super cheap for a company with a drug that has a ~90%+ chance of getting approved and will have peak sales of $300M+ and potentially much more with other indications. In my opinion the stock has room to grow 4x+ and that's a conservative guess.
Will end the day green!...
This is ridiculous?......... But typical following dilution.
In the short-term, we should see this move back up....... In the mid-term we should see new cars our driveways!
This closes down a little bit, but I think tomorrow it'll be near 5.60